Cointime

Beta Bionics

company

About

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet.

  • 51 - 100

Highlights

Total Funding Amount
$125M
Funding Rounds
3
Investors
2

Details

Last Funding Type
Series B
Last Funding Money Raised
$63M
Industries
Biotechnology,Diabetes,Medical Device
Founded date
Oct 21, 2015
Number Of Employee
51 - 100
Operating Status
Active

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.

Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$125M
Beta Bionics has raised a total of $125M in funding over 2 rounds. Their latest funding was raised on Feb 17, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 17, 2022 Series C $57M 1 — — Detail
Jan 8, 2019 Series B $63M 1 — — Detail
Dec 31, 2015 Series A $5M 1 Novo Nordisk — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Beta Bionics is funded by 2 investors. Novo Nordisk and Dexcom are the most recent investors.
Investor Name Lead Investor Funding Round
Novo Nordisk — Series C
Dexcom — Series B
Cointime
Chủ Đề
Công Ty